Phase II Trial of Bortezomib Plus Low Dose Dexamethasone and Doxorubicin With Acetyl-L-Carnitine for Neuroprotection in Patients With Previously Treated Multiple Myeloma.

Trial Profile

Phase II Trial of Bortezomib Plus Low Dose Dexamethasone and Doxorubicin With Acetyl-L-Carnitine for Neuroprotection in Patients With Previously Treated Multiple Myeloma.

Completed
Phase of Trial: Phase II

Latest Information Update: 18 Jan 2017

At a glance

  • Drugs Bortezomib (Primary) ; Dexamethasone (Primary) ; Doxorubicin (Primary) ; Levacecarnine (Primary)
  • Indications Multiple myeloma
  • Focus Therapeutic Use
  • Most Recent Events

    • 27 Jan 2012 Actual end date (Dec 2010) added as reported by ClinicalTrials.gov.
    • 27 Jan 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 08 Nov 2011 Planned end date changed from 1 Dec 2010 to 1 Jul 2012 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top